{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:50:58Z","timestamp":1772941858633,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jmgm.2025.109156","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T23:22:33Z","timestamp":1755904953000},"page":"109156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Revealing drug interactions: A computational study of non-P450 metabolizing enzymes"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-1461","authenticated-orcid":false,"given":"Muslum","family":"Yildiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jmgm.2025.109156_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2133\/dmpk.21.357","article-title":"Tissue-specific MRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes","volume":"21","author":"Nishimura","year":"2006","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.jmgm.2025.109156_bib2","article-title":"Cytochrome P450 monooxygenase","author":"Yan","year":"2023","journal-title":"Worldwide Protein Data Bank"},{"issue":"2","key":"10.1016\/j.jmgm.2025.109156_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/00498254.2019.1610584","article-title":"In vitro inhibitory effects of phellodendrine on human liver cytochrome P450 enzymes","volume":"50","author":"Li","year":"2019","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.jmgm.2025.109156_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1365-2125.2002.01660.x","article-title":"Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase","volume":"54","author":"Sandberg","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jmgm.2025.109156_bib5","series-title":"Role of Intestinal Cytochromes P450 in Drug Disposition. Drug Metabolizing Enzymes","first-page":"421","author":"Thummel","year":"2003"},{"issue":"1","key":"10.1016\/j.jmgm.2025.109156_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.pharmtox.45.120403.100010","article-title":"Cytochrome P450 activation of arylamines and heterocyclic amines","volume":"45","author":"Kim","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.jmgm.2025.109156_bib7","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1124\/dmd.114.056903","article-title":"Carbon-carbon bond cleavage in activation of the prodrug nabumetone","volume":"42","author":"Varfaj","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"2\u20133","key":"10.1016\/j.jmgm.2025.109156_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tox.2006.11.052","article-title":"Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen","volume":"230","author":"Moffit","year":"2007","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.jmgm.2025.109156_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/03602532.2016.1225756","article-title":"Non-cytochrome P450-mediated bioactivation and its toxicological relevance","volume":"48","author":"Gan","year":"2016","journal-title":"Drug Metab. Rev."},{"issue":"8","key":"10.1016\/j.jmgm.2025.109156_bib10","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/dmd.116.070763","article-title":"Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015","volume":"44","author":"Cerny","year":"2016","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.jmgm.2025.109156_bib11","series-title":"Non-P450 Mediated Oxidative Metabolism of Xenobiotics. Drug Metabolizing Enzymes","first-page":"483","author":"Lang","year":"2003"},{"issue":"1","key":"10.1016\/j.jmgm.2025.109156_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-pharmtox-052220-105907","article-title":"Non-P450 drug-metabolizing enzymes: contribution to drug disposition, toxicity, and development","volume":"62","author":"Fukami","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.jmgm.2025.109156_bib13","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1172\/JCI110903","volume":"71","author":"Loose","year":"1983","journal-title":"Eur. J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jmgm.2025.109156_bib14","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-019-0294-1","article-title":"Quantitative prediction of human hepatic clearance for P450 and non-P450 substrates from in vivo monkey pharmacokinetics study and in vitro metabolic stability tests using hepatocytes","volume":"21","author":"Nishimuta","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.jmgm.2025.109156_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114887","article-title":"Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans","volume":"197","author":"Uno","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.jmgm.2025.109156_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/dmd.121.000774","article-title":"Comparison of tissue abundance of non-cytochrome P450 drug-metabolizing enzymes by quantitative proteomics between humans and laboratory animal species","volume":"50","author":"Basit","year":"2022","journal-title":"Drug Metabol. Dispos."},{"issue":"7","key":"10.1016\/j.jmgm.2025.109156_bib17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/00498254.2019.1704097","article-title":"A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes","volume":"50","author":"Matsumoto","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jmgm.2025.109156_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108020","article-title":"Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: focus on the regulation of gene expression and enzyme activity","volume":"233","author":"Pang","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jmgm.2025.109156_bib19","series-title":"CYTOCHROME P450: in Vitro Methods and Protocols","first-page":"277","article-title":"Differentiation of cytochrome P450-mediated from non-CYP-mediated metabolism: aldehyde oxidase and xanthine oxidoreductase","author":"Kozminski","year":"2021"},{"key":"10.1016\/j.jmgm.2025.109156_bib20","series-title":"CYTOCHROME P450: in Vitro Methods and Protocols","first-page":"27","article-title":"Characteristics of major drug metabolizing cytochrome P450 enzymes","author":"Johnson","year":"2021"},{"key":"10.1016\/j.jmgm.2025.109156_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jechem.2022.12.021","article-title":"Creation of cytochrome P450 catalysis depending on a non-natural cofactor for fatty acid hydroxylation","volume":"79","author":"Li","year":"2023","journal-title":"J. Energy Chem."},{"issue":"7","key":"10.1016\/j.jmgm.2025.109156_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1124\/dmd.120.090738","article-title":"Regional proteomic quantification of clinically relevant non-cytochrome P450 enzymes along the human small intestine","volume":"48","author":"Zhang","year":"2020","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.jmgm.2025.109156_bib23","series-title":"CYTOCHROME P450: in Vitro Methods and Protocols","first-page":"341","article-title":"Simultaneously assessing concentration changes in 17 biochemical pathways as a result of drug dosing and cytochrome P450 and non-cytochrome P450-mediated metabolism: a quasi-untargeted metabolomics LC\/MS assay","author":"Masucci","year":"2021"},{"key":"10.1016\/j.jmgm.2025.109156_bib24","series-title":"CYTOCHROME P450: in Vitro Methods and Protocols","first-page":"359","article-title":"Assessing amino acid concentration changes as a result of drug dosing and cytochrome P450 and non-cytochrome P450-mediated metabolism","author":"Bingol","year":"2021"},{"key":"10.1016\/j.jmgm.2025.109156_bib25","series-title":"CYTOCHROME P450: in Vitro Methods and Protocols","first-page":"319","article-title":"Simultaneously assessing concentration changes in 20 biochemical pathways as a result of drug dosing and cytochrome P450 and non-cytochrome P450-mediated metabolism: an untargeted metabolomics GC\/MS assay","author":"Lin","year":"2021"},{"key":"10.1016\/j.jmgm.2025.109156_bib26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1517\/17425255.2013.796929","article-title":"Glycine conjugation: importance in metabolism, the role of Glycine N-acyltransferase, and factors that influence interindividual variation","author":"Badenhorst","year":"2013","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.jmgm.2025.109156_bib27","volume":"vol. 21","author":"Liston","year":"2001"},{"issue":"8","key":"10.1016\/j.jmgm.2025.109156_bib28","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.116.071753","article-title":"Cytochrome P450 and non-cytochrome P450 oxidative metabolism: contributions to the pharmacokinetics, safety, and efficacy of xenobiotics","volume":"44","author":"Foti","year":"2016","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.jmgm.2025.109156_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115250","article-title":"Emerging role of carboxylesterases in nonalcoholic fatty liver disease","volume":"205","author":"Liu","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.jmgm.2025.109156_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.bbapap.2014.01.003","article-title":"Crystal structures of two Bacillus carboxylesterases with different enantioselectivities","volume":"1844","author":"Rozeboom","year":"2014","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"issue":"5","key":"10.1016\/j.jmgm.2025.109156_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.jmgm.2025.109156_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jmgm.2025.109156_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jbt.20178","article-title":"Human carboxylesterases and their role in xenobiotic and endobiotic metabolism","volume":"21","author":"Ross","year":"2007","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"11","key":"10.1016\/j.jmgm.2025.109156_bib34","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2011.08.003","article-title":"Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine","volume":"82","author":"Nakajima","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jmgm.2025.109156_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2016.07.007","article-title":"Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity","volume":"116","author":"Fukami","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.jmgm.2025.109156_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12870","article-title":"In vitro deacetylation of N-acetylserotonin by arylacetamide deacetylase","volume":"75","author":"Huang","year":"2023","journal-title":"J. Pineal Res."},{"issue":"6","key":"10.1016\/j.jmgm.2025.109156_bib37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1124\/dmd.122.001113","article-title":"Characterization of enzymes involved in nintedanib metabolism in HumansS","volume":"51","author":"Nakashima","year":"2023","journal-title":"Drug Metabol. Dispos."},{"issue":"4","key":"10.1016\/j.jmgm.2025.109156_bib38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1124\/dmd.111.043067","article-title":"Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse","volume":"40","author":"Kobayashi","year":"2012","journal-title":"Drug Metabol. Dispos."},{"issue":"6","key":"10.1016\/j.jmgm.2025.109156_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12060516","article-title":"KIAA1363-A multifunctional enzyme in xenobiotic detoxification and lipid ester hydrolysis","volume":"12","author":"Wagner","year":"2022","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.jmgm.2025.109156_bib40","article-title":"Impact of AADAC gene expression on prognosis in patients with borrmann type III advanced gastric cancer","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jmgm.2025.109156_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s43141-022-00443-z","article-title":"Characterization, comparative, and functional analysis of arylacetamide deacetylase from gnathostomata organisms","volume":"20","author":"Diaz-Vidal","year":"2022","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"10.1016\/j.jmgm.2025.109156_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114842","article-title":"Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency","volume":"195","author":"Nagaoka","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.jmgm.2025.109156_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5468\/ogs.21237","article-title":"Signature of arylacetamide deacetylase expression is associated with prognosis and immune infiltration in ovarian cancer","volume":"65","author":"Feng","year":"2022","journal-title":"Obstet Gynecol. Sci."},{"key":"10.1016\/j.jmgm.2025.109156_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115010","article-title":"PPAR alpha regulates the expression of human arylacetamide deacetylase involved in drug hydrolysis and lipid metabolism","volume":"199","author":"Morikawa","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.jmgm.2025.109156_bib45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1124\/dmd.115.068221","article-title":"Arylacetamide deacetylase is responsible for activation of prasugrel in human and dog","volume":"44","author":"Kurokawa","year":"2016","journal-title":"Drug Metabol. Dispos."},{"issue":"4","key":"10.1016\/j.jmgm.2025.109156_bib46","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/dmd.120.000295","article-title":"Role of human arylacetamide deacetylase (AADAC) on hydrolysis of eslicarbazepine acetate and effects of AADAC genetic polymorphisms on hydrolase activity","volume":"49","author":"Hirosawa","year":"2021","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.jmgm.2025.109156_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119896","article-title":"Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans","volume":"284","author":"Sakai","year":"2021","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.jmgm.2025.109156_bib48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nsmb767","article-title":"Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes","volume":"11","author":"Harel","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6","key":"10.1016\/j.jmgm.2025.109156_bib49","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1194\/jlr.M400511-JLR200","article-title":"Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities","volume":"46","author":"Draganov","year":"2005","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/j.jmgm.2025.109156_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24097764","article-title":"Proteomic exploration of paraoxonase 1 function in health and disease","volume":"24","author":"Jakubowski","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.jmgm.2025.109156_bib51","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1124\/dmd.111.038141","article-title":"Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis","volume":"39","author":"Hioki","year":"2011","journal-title":"Drug Metabol. Dispos."},{"issue":"2","key":"10.1016\/j.jmgm.2025.109156_bib52","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/dmd.111.041475","article-title":"Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism","volume":"40","author":"Ishizuka","year":"2012","journal-title":"Drug Metabol. Dispos."},{"issue":"12","key":"10.1016\/j.jmgm.2025.109156_bib53","doi-asserted-by":"crossref","first-page":"9240","DOI":"10.1074\/jbc.M111.271288","article-title":"Human alpha\/beta hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver","volume":"287","author":"Iwamura","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.jmgm.2025.109156_bib54","doi-asserted-by":"crossref","first-page":"9759","DOI":"10.1021\/acs.jmedchem.1c00624","article-title":"Alpha\/beta-hydrolase domain (ABHD) inhibitors as new potential therapeutic options against lipid-related diseases","volume":"64","author":"Bononi","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jmgm.2025.109156_bib55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1109\/TCBB.2015.2459680","article-title":"Algorithms for analyzing dynamics of tunnels in macromolecules","volume":"13","author":"Pavelka","year":"2016","journal-title":"IEEE ACM Trans. Comput. Biol. Bioinf"},{"issue":"12","key":"10.1016\/j.jmgm.2025.109156_bib56","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.2174\/1381612811319120019","article-title":"Binding site detection and druggability prediction of protein targets for structure-based drug design","volume":"19","author":"Yuan","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"20","key":"10.1016\/j.jmgm.2025.109156_bib57","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","article-title":"AmberTools","volume":"63","author":"Case","year":"2023","journal-title":"J. Chem. Inf. Model."},{"issue":"6","key":"10.1016\/j.jmgm.2025.109156_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112609","article-title":"High-resolution structural-omics of human liver enzymes","volume":"42","author":"Su","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.jmgm.2025.109156_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115301","article-title":"Highly selective butyrylcholinesterase inhibitors related to amaryllidaceae alkaloids - design, synthesis, and biological evaluation","volume":"252","author":"Pidany","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.jmgm.2025.109156_bib60","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1074\/jbc.M709530200","article-title":"Molecular basis of prodrug activation by human valacyclovirase, an \u03b1-amino acid ester hydrolase","volume":"283","author":"Lai","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jmgm.2025.109156_bib61","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1124\/mol.109.062356","article-title":"Human carboxylesterase 1 stereoselectively binds the nerve agent cyclosarin and spontaneously hydrolyzes the nerve agent sarin","volume":"77","author":"Hemmert","year":"2010","journal-title":"Mol. Pharmacol."}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326325002165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326325002165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:21:14Z","timestamp":1772882474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326325002165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":61,"alternative-id":["S1093326325002165"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2025.109156","relation":{},"ISSN":["1093-3263"],"issn-type":[{"value":"1093-3263","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revealing drug interactions: A computational study of non-P450 metabolizing enzymes","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2025.109156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109156"}}